Clinical Commentary Conidiobolomycosis JOHN SCHUMACHER* and JIM SCHUMACHER† Department of Clinical Sciences, J

Total Page:16

File Type:pdf, Size:1020Kb

Clinical Commentary Conidiobolomycosis JOHN SCHUMACHER* and JIM SCHUMACHER† Department of Clinical Sciences, J EQUINE VETERINARY EDUCATION / AE / september 2007 405 Clinical Commentary Conidiobolomycosis JOHN SCHUMACHER* AND JIM SCHUMACHER† Department of Clinical Sciences, J. T. Vaughan Teaching Hospital, College of Veterinary Medicine, Auburn University, Alabama 36849-5522; and †Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee 77901-1071, USA. Conidiobolomycosis is a pyogranulomatous disease of the by pythiosis, lesions caused by C. coronatus do not appear to upper portion of the respiratory tract of horses, man and, be pruritic. These lesions may be similar in appearance to an rarely, other species, caused by infection of the mucosa and ethmoidal haematoma, nasal neoplasia, nasal granulomas submucosa by the fungus, Conidiobolus coronatus. caused by periapical infection of a maxillary premolar, and Conidiobolus was once included in the genus Entomophthora granulomas caused by other fungi that infect the nasal and hence is sometimes referred to as Entomophthora mucosa, such as Rhinosporidium seeberi, Cryptococcus coronatus (Richardson and Shankland 1999). neoforman and Coccidioides immitis. Conidiobolomycosis is part of the disease complex known Nasal or pharyngeal lesions can be biopsied using a mare as equine phycomycosis, which also includes Pythium endometrial biopsy rod guided endoscopically to the lesion. insidiosum (formerly Hyphomyces destruens) and Basidiobolus Granulation tissue, infiltrated by numerous eosinophils, haptosporus (Miller and Campbell 1982, 1984; Miller 1983a). neutrophils, macrophages, plasma cells, lymphocytes, giant Lesions of conidiobolomycosis are found in the upper portion cells and hyphae surrounding necrotic masses, is seen during of the respiratory tract, whereas lesions of pythiosis and histological examination of lesions (French et al. 1985; Zamos basidiobolomycosis are primarily found on the skin and et al. 1996; Steiger and Williams 2000; Taintor et al. 2004). subcutis of the trunk and limbs (Miller 1983b). Special stains, such as Gomori’s silver stain may be required to Infection by Conidiobolus, which is found in the soil and identify hyphae. Diagnosis of conidiobolomycosis is based on decaying organic material (Miller 1983b), can occur while the clinical signs, gross and histological appearance of the lesion, horse is grazing. Because damp and decaying bedding and identification of the causative organism. provides an ideal habitat for the growth of the fungus, Conidiobolomycosis can also be identified from clinical infection may occur when the horse sleeps on decaying tissue samples by PCR (Imhof et al. 2003) or by an damp bedding (Humber et al. 1989). Whether or not the immunodiffusion test, using serum from the affected horse respiratory epithelium must be damaged for entry of the (Kaufman et al. 1990; Steiger and Williams 2000). organism is not known, but bacterial or viral infection of the Treatment of horses affected by conidiobolomycosis respiratory epithelium may perhaps cause mucosal damage includes excision of lesions and parenteral and topical and provide entry for the fungal conidia (Hanselka 1977). administration of antifungal drugs. Excision of nasal and Infection does not seem to be associated with nasopharyngeal lesions of conidiobolomycosis is difficult because lesions at these locations are usually surgically immunodeficiency (Chandler 1997). inaccessible. Although horses with pythiosis have been The most common clinical sign of the disease is a successfully treated with vaccine made from P. insidiosum sanguinolent, mucopurulent nasal discharge (French et al. (Miller 1981; Miller et al. 1983; Mendoza and Newton 2005), 1985; Zamos et al. 1996; Taintor et al. 2004; Robinson et al. immunotherapy for treatment of horses with 2007). One affected horse had a chronic cough caused by conidiobolomycosis does not seem to be effective infection of the proximal half of the trachea (Steiger and (Taintor et al. 2004; R. Glass, L. Mendoza, personal Williams 2000). Granulomas can sometimes be seen at the communications). external nares, but endoscopic examination of the upper Data concerning the in vitro activity of antifungal agents portion of the respiratory tract is usually necessary to observe against Conidiobolus is very limited. Iodides are the most the lesions. C. coronatus causes small growths, 1–3 cm in commonly recommended drugs for treatment of diameter, within the nasal cavity and slightly larger growths, conidiobolomycosis in man (Restrepo 1994) and horses (Scott 1–5 cm diameter, on the external nares. Unlike lesions caused and Miller 2003). Although the most commonly recommended iodide for treatment of horses affected with *Author to whom correspondence should be addressed. conidiobolomycosis is potassium iodide, organic iodide 406 EQUINE VETERINARY EDUCATION / AE / september 2007 (ethylenediamine dihydroiodide, EDDI) may offer advantages Humber, R.A., Brown, C.C. and Kornegay, R.W. (1989) Equine over inorganic iodide (Morris 1983). This iodide is less zygomycosis caused by Conidiobolus lamprauges. J. clin. expensive and maintains high tissue concentrations for a Microbiol. 27, 573-576. longer time than sodium iodide. Many different protocols of Imhof, A., Schaer, C., Schoedon, G., Schaer, D.J., Walter, R.B., administration have been reported (Zamos et al. 1996; Steiger Schaffner, A. and Schneemann, M. (2003) Rapid detection of pathogenic fungi from clinical specimens using LightCycler and Williams 2000; Taintor et al. 2004). EDDI is administered real-time fluorescence PCR. Eur. J. Clin. Microbiol. Infect. Dis. at 20–40 mg/kg bwt, per os, once daily, indefinitely. Sodium 22, 558-560. iodide (67 mg/kg bwt, i.v. once daily) is often administered for Kaufman, L., Mendoza, L. and Standard, P.G. (1990) Immunodiffusion 2–5 days before therapy with orally administered iodide is test for serodiagnosing subcutaneous zygomycosis. J. clin. begun. The mechanism of action of iodide against fungal Microbiol. 28, 1887-1890. organisms is not known. In the authors’ experience, cessation Korenek, N.L., Legendre, A.M. and Andrews, F.M. (1994) Treatment of of therapy with iodides before complete resolution of mycotic rhinitis with itraconazole in three horses. J. vet. Int. Med. conidiobolomycosis seems to cause the disease to be 8, 224-227. refractory to further treatment with iodide. Mendoza, L. and Newton, J.C. (2005) Immunology and Whether or not the fungus has receptors for immunotherapy of the infections caused by Phythium insidiosum. amphotericin B is not known, but several horses have Med. Mycol. 43, 477-486. reportedly responded to intralesional administration of this Miller, R.I. (1981) Treatment of equine phycomycosis by drug (French and Haynes 1985; Zamos et al. 1996). One immunotherapy and surgery. Aust. vet. J. 57, 377-382. horse was also treated with sodium and potassium iodide, Miller, R.I. (1983a) Equine phycomycosis. Comp. cont. Educ. pract. thus obscuring the effect of amphotericin B (Zamos et al. Vet. 5, 472-478. 1996). Literature concerning treatment in man infected with Miller, R.I. (1983b) Nomenclature of fungal diseases, Letter to the Conidiobolus spp. was reviewed, and the outcome of Editor. Vet. Pathol. 20, 251-253. patients treated with amphotericin B was judged to be poor Miller, R.I. and Campbell, R.S. (1982) Clinical observations on equine (Guarro et al. 1999). phycomycosis. Aust. vet. J. 58, 221-226. In an in vitro study, Conidiobolus spp. were resistant to Miller, R.I. and Campbell (1984) The comparative pathology of equine amphotericin B, ketoconazole, miconizole, itraconizole, cutaneous phycomycosis. Vet. Pathol. 21, 325-332. fluconazole, and flucytosine (Guarro et al. 1999). Two Miller, R.I., Wold, D., Lindsay, W.A., Beadle, R.E., McClure, J.J., pregnant mares affected with conidiobolomycosis, however, McClure, J.R. and McCoy, D.J. (1983) Complications associated were treated successfully with orally administered fluconazole with immunotherapy of equine phycomycosis. J. Am. vet. med. (5 mg/kg bwt, q. 12 h, per os, for 6 weeks) (Taintor et al. Ass. 182, 1227-1229. 2004). Although fluconazole is reported to have teratogenic Morris, P. (1983) Sporotrichosis. In: Current Therapy in Equine and embryo toxic effects when used in high doses, foals born Medicine, Ed: N.E. Robinson, W.B. Saunders Co, Philadelphia. to these mares appeared normal. pp 555-556. Treatment of affected horses with the similar antifungal Prades, M., Brown, M.P. and Gronwall, R. (1989) Body fluid and drug, ketaconazole is likely to be unsuccessful, because this endometrial concentrations of ketaconazole in mares after drug is absorbed poorly from the horse’s gastrointestinal tract intravenous injection or repeated lavage. Equine vet. J. 21, 211-214. (Prades et al. 1989). A horse with nasal lesions caused by C. coronatus had no resolution of lesions after 4.5 months of Restrepo, A. (1994) Treatment of tropical mycoses. J. Am. Acad. Dermatol. 31, S91-102. treatment with itraconazole (Korenek et al. 1994). Human patients have been treated for conidiobolomycosis with Richardson, M.D. and Shankland, G.S. (1999) Rhizopus, Rhizomucor, Absidia, and other agents of systemic and subcutaneous trimethoprim-sulphamethoxazole (Restrepo 1994), but we are zygomycoses. In: Manual of Clinical Microbiology, Eds: P.R. unaware of any reports of this drug being used to treat horses Murray, E.J. Baron and M.A. Pfaller, ASM Press, Washington DC. with conidiobolomycosis. pp 1152-1163. Robinson, C.S., Robertson, J.T., Reed, S.M. and Pinchbeck, L.R.
Recommended publications
  • Successful Management of 3 Dogs with Colonic Pythiosis Using Itraconzaole, Terbinafine, and Prednisone
    UC Davis UC Davis Previously Published Works Title Successful management of 3 dogs with colonic pythiosis using itraconzaole, terbinafine, and prednisone. Permalink https://escholarship.org/uc/item/2119g65v Journal Journal of veterinary internal medicine, 33(3) ISSN 0891-6640 Authors Reagan, Krystle L Marks, Stanley L Pesavento, Patricia A et al. Publication Date 2019-05-01 DOI 10.1111/jvim.15506 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Received: 19 January 2019 Accepted: 8 April 2019 DOI: 10.1111/jvim.15506 CASE REPORT Successful management of 3 dogs with colonic pythiosis using itraconzaole, terbinafine, and prednisone Krystle L. Reagan1 | Stanley L. Marks2 | Patricia A. Pesavento3 | Ann Della Maggiore1 | Bing Y. Zhu1 | Amy M. Grooters4 1Veterinary Medical Teaching Hospital, University of California Davis, Davis, California Abstract 2Department of Medicine and Epidemiology, Gastrointestinal (GI) pythiosis is a severe and often fatal disease in dogs that School of Veterinary Medicine, University of traditionally has been poorly responsive to medical treatment. Although aggressive sur- California, Davis, California 3Department of Pathology, Microbiology, and gical resection with wide margins is the most consistently effective treatment, lesion Immunology, School of Veterinary Medicine, location and extent often preclude complete resection. Recently, it has been suggested University of California, Davis, California that the addition of anti-inflammatory doses of corticosteroids may improve outcome 4Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State in dogs with nonresectable GI pythiosis. This report describes 3 dogs with colonic University, Baton Rouge, Louisiana pythiosis in which complete resolution of clinical signs, regression of colonic masses, Correspondence and progressive decreases in serological titers were observed after treatment with Krystle L.
    [Show full text]
  • Lactoferrin, Chitosan and Melaleuca Alternifolia—Natural Products That
    b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 9 (2 0 1 8) 212–219 ht tp://www.bjmicrobiol.com.br/ Review Lactoferrin, chitosan and Melaleuca alternifolia—natural products that show promise in candidiasis treatment ∗ Lorena de Oliveira Felipe , Willer Ferreira da Silva Júnior, Katialaine Corrêa de Araújo, Daniela Leite Fabrino Universidade Federal de São João del-Rei/Campus Alto Paraopeba, Minas Gerais, MG, Brazil a r t i c l e i n f o a b s t r a c t Article history: The evolution of microorganisms resistant to many medicines has become a major chal- Received 18 August 2016 lenge for the scientific community around the world. Motivated by the gravity of such a Accepted 26 May 2017 situation, the World Health Organization released a report in 2014 with the aim of providing Available online 11 November 2017 updated information on this critical scenario. Among the most worrying microorganisms, Associate Editor: Luis Henrique species from the genus Candida have exhibited a high rate of resistance to antifungal drugs. Guimarães Therefore, the objective of this review is to show that the use of natural products (extracts or isolated biomolecules), along with conventional antifungal therapy, can be a very promising Keywords: strategy to overcome microbial multiresistance. Some promising alternatives are essential Candida oils of Melaleuca alternifolia (mainly composed of terpinen-4-ol, a type of monoterpene), lacto- Lactoferrin ferrin (a peptide isolated from milk) and chitosan (a copolymer from chitin).
    [Show full text]
  • Sublingual Pythiosis in a Cat Jessica Sonia Fortin1, Michael John Calcutt2 and Dae Young Kim1*
    Fortin et al. Acta Vet Scand (2017) 59:63 DOI 10.1186/s13028-017-0330-z Acta Veterinaria Scandinavica CASE REPORT Open Access Sublingual pythiosis in a cat Jessica Sonia Fortin1, Michael John Calcutt2 and Dae Young Kim1* Abstract Background: Pythiosis is a potentially fatal but non-contagious disease afecting humans and animals living in tropi- cal and subtropical climates, but is also reasonably widespread in temperate climates, throughout the world. The most commonly reported afected animal species with pythiosis are equine and canine, with fewer cases in bovine and feline. Extracutaneous infections caused by Pythium insidiosum have been rarely described in the cat. Case presentation: Sublingual pythiosis was diagnosed in a 2-year-old, male, Domestic Shorthair cat. The cat had a multilobulated, sublingual mass present for 3 months. Histopathological examination revealed severe multifocal coalescing eosinophilic granulomatous infammation. Centers of the infammation contained hyphae that were 3–7 μm-wide, non-parallel, uncommonly septate and rarely branching. The fungal-like organism was identifed as P. insid- iosum by polymerase chain reaction and subsequent amplicon sequencing. Conclusions: Only a few feline pythiosis cases have been reported and, when encountered, it usually causes granu- lomatous diseases of the skin or gastrointestinal tract. This case presents an unusual manifestation of feline pythiosis, representing the frst involving the oral cavity in cats or dogs. Keywords: Eosinophilic granulomatous infammation, Feline, Hyphae, Pythium insidiosum, Sublingual mass Background trauma in Afghanistan [5]. Animals afected by the dis- Pythiosis is a potentially fatal but non-contagious disease ease are often younger and exposed to warm, freshwa- afecting humans and animals living in tropical and sub- ter habitats [1].
    [Show full text]
  • The Epidemiology and Clinical Features of Balamuthia Mandrillaris Disease in the United States, 1974 – 2016
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Clin Infect Manuscript Author Dis. Author manuscript; Manuscript Author available in PMC 2020 August 28. Published in final edited form as: Clin Infect Dis. 2019 May 17; 68(11): 1815–1822. doi:10.1093/cid/ciy813. The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974 – 2016 Jennifer R. Cope1, Janet Landa1,2, Hannah Nethercut1,3, Sarah A. Collier1, Carol Glaser4, Melanie Moser5, Raghuveer Puttagunta1, Jonathan S. Yoder1, Ibne K. Ali1, Sharon L. Roy6 1Waterborne Disease Prevention Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA 2James A. Ferguson Emerging Infectious Diseases Fellowship Program, Baltimore, MD, USA 3Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA 4Kaiser Permanente, San Francisco, CA, USA 5Office of Financial Resources, Centers for Disease Control and Prevention Atlanta, GA, USA 6Parasitic Diseases Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA Abstract Background—Balamuthia mandrillaris is a free-living ameba that causes rare, nearly always fatal disease in humans and animals worldwide. B. mandrillaris has been isolated from soil, dust, and water. Initial entry of Balamuthia into the body is likely via the skin or lungs. To date, only individual case reports and small case series have been published. Methods—The Centers for Disease Control and Prevention (CDC) maintains a free-living ameba (FLA) registry and laboratory. To be entered into the registry, a Balamuthia case must be laboratory-confirmed.
    [Show full text]
  • Idweek 2013 Miltefosine Poster Final.Pdf
    Increased Patient Survival: Miltefosine for Treatment of Free-living Ameba Infections Caused by Acanthamoeba, Balamuthia, and Naegleria Jennifer R. Cope, Sharon L. Roy, Jonathan S. Yoder, Michael J. Beach BACKGROUND RESULTS CONCLUSIONS Granulomatous amebic encephalitis (GAE) Acanthamoeba Balamuthia mandrillaris Survival in Patients Who Received Miltefosine vs. Patients Who Did Not Receive Miltefosine . Number of Acanthamoeba, Balamuthia, and Naegleria infections . Subacute to chronic central nervous system infection treated with a miltefosine-containing regimen is small. Caused by the free-living amebae (FLA) Balamuthia mandrillaris and N Received Did Not Receive P- . Miltefosine-containing treatment regimen does offer a Acanthamoeba spp. Miltefosine* Miltefosine value significant survival advantage for these often fatal infections. Often fatal . CDC should provide drug to clinicians for FLA infections under an Symptoms of GAE Survived/Total (%) Survived/Total (%) expanded access IND until it becomes commercially available in Personality and . Photophobia . Non-keratitis the United States. behavioral changes . Seizures Acanthamoeba 63 5/7 (71) 9/56 (16) 0.005 . Depressed mental . Cranial nerve status dysfunction infections (1955–2012) . Fever . Visual Loss Balamuthia infections Photomicrographs of Acanthamoeba and Balamuthia (1974–2012) 60 6/14 (43) 6/46 (13) 0.05 Brain imaging trophozoites . Single or multiple ring-enhancing lesions Naegleria fowleri Naegleria infections 2/4 (50) 1/65 (1.5) 0.02 CDC’s Free-living Ameba Program Activities Magnetic resonance imaging (MRI) of patient with Balamuthia GAE (1962–2013) 69 . Providing 24/7 diagnostic services and clinical guidance to health professionals, including provision of miltefosine when indicated Primary amebic meningoencephalitis (PAM) * Miltefosine is given in combination with other antibiotics and antifungals such as: .
    [Show full text]
  • ANCOBON® (Flucytosine) Capsules Rx Only
    ANCOBON® (flucytosine) capsules Rx only WARNING Use with extreme caution in patients with impaired renal function. Close monitoring of hematologic, renal and hepatic status of all patients is essential. These instructions should be thoroughly reviewed before administration of ANCOBON. DESCRIPTION ANCOBON (flucytosine), an antifungal agent, is available as 250 mg and 500 mg capsules for oral administration. In addition to the active ingredient of flucytosine, each capsule contains corn starch, lactose and talc. The 250 mg capsule shell contains black iron oxide, D&C Yellow No. 10, FD&C Blue No. 1, FD&C Yellow No. 6, gelatin and titanium dioxide. The 500 mg capsule shell contains black iron oxide, gelatin and titanium dioxide. Chemically, flucytosine is 5-fluorocytosine, a fluorinated pyrimidine which is related to fluorouracil and floxuridine. It is a white to off-white crystalline powder with a molecular weight of 129.09 and the following structural formula: CLINICAL PHARMACOLOGY Flucytosine is rapidly and virtually completely absorbed following oral administration. ANCOBON is not metabolized significantly when given orally to man. Bioavailability estimated by comparing the area under the curve of serum concentrations after oral and intravenous administration showed 78% to 89% absorption of the oral dose. Peak serum concentrations of 30 to 40 mcg/mL were reached within 2 hours of administration of a 2 g oral dose to normal subjects. Other studies revealed mean serum concentrations of approximately 70 to 80 mcg/mL 1 to 2 hours after a dose in patients with normal renal function receiving a 6-week regimen of flucytosine (150 mg/kg/day given in divided doses every 6 hours) in combination with amphotericin B.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • World Health Organization Model List of Essential Medicines, 21St List, 2019
    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]
  • Preferred Drug List
    October 2021 Preferred Drug List The Preferred Drug List, administered by CVS Caremark® on behalf of Siemens, is a guide within select therapeutic categories for clients, plan members and health care providers. Generics should be considered the first line of prescribing. If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. PLAN MEMBER HEALTH CARE PROVIDER Your benefit plan provides you with a prescription benefit program Your patient is covered under a prescription benefit plan administered administered by CVS Caremark. Ask your doctor to consider by CVS Caremark. As a way to help manage health care costs, prescribing, when medically appropriate, a preferred medicine from authorize generic substitution whenever possible. If you believe a this list. Take this list along when you or a covered family member brand-name product is necessary, consider prescribing a brand name sees a doctor. on this list. Please note: Please note: • Your specific prescription benefit plan design may not cover • Generics should be considered the first line of prescribing. certain products or categories, regardless of their appearance in • This drug list represents a summary of prescription coverage. It is this document. Products recently approved by the U.S. Food and not all-inclusive and does not guarantee coverage.
    [Show full text]
  • Successful Treatment of Granulomatous Amoebic Encephalitis with Combination Antimicrobial Therapy
    □ CASE REPORT □ Successful Treatment of Granulomatous Amoebic Encephalitis with Combination Antimicrobial Therapy Hideki Kato 1, Shigehisa Mitake 1, Hiroyuki Yuasa 1, Shigemasa Hayashi 2, Tatsuru Hara 3 and Noriyuki Matsukawa 4 Abstract Granulomatous amoebic encephalitis (GAE) is a rare but fatal infection. Due to its nonspecific symptoms and laboratory and neuroradiological findings, it is rarely diagnosed antemortem. We herein present the case of a 72-year-old Japanese woman who was diagnosed with GAE following the detection of a pathogen simi- lar to Balamuthia mandrillaris under a microscopic examination of cerebrospinal fluid sediment and who achieved remission with combination antimicrobial therapy. There are no previous reports of pathogens simi- lar to B. mandrillaris being detected in cerebrospinal fluid antemortem; therefore, this case may be used as a benchmark for further studies. Key words: granulomatous amoebic encephalitis (GAE), antimicrobial therapy, free-living amoebae, cerebrospinal fluid (CSF) (Intern Med 52: 1977-1981, 2013) (DOI: 10.2169/internalmedicine.52.0299) cases of survival. Because GAE is a rare disease with non- Introduction specific symptoms, making the diagnosis antemortem is dif- ficult. Additionally, there are no reports in which the Meningoencephalitis caused by free-living amoebae in- Balamuthia-like amoeba itself was found in cerebrospinal cludes two clinical entities: primary amoebic meningoen- fluid (CSF) (4). The present report describes a case of GAE cephalitis (PAM) and granulomatous amoebic encephalitis caused by amoebae with Balamuthia-like morphological (GAE). Both have a poor prognosis, usually resulting in characteristics detected in the CSF in which we administered death (1, 2). The pathogenic organism responsible for PAM antimicrobial therapy and were able to save the patient’s is Naegleria fowleri.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Swamp Cancer-The Imaging of Pythiosis
    IVRA Pythiosis Mylene Auger, DVM, DACVR Animages, Longueuil, QC, Canada Pythiosis (Pythium insidiosumIVRA) ▪ Aquatic pathogen in class Oomycetes ▪ Fungal -like microbes but differ from true fungi – Produce motile, flagellate zoospores – Have cell walls that contain cellulose and β -glucan but not chitin – Resemble algae more than fungi ▪ Infective stage thought to be aquatic zoospores – Released into warm water environments – Possess strong tropism for plant tissue and mammalian open skin – Encysts in damaged skin or GI mucosa – No evidence of transmission between hosts Pythiosis (Pythium insidiosumIVRA) ▪ Mostly reported in Gulf Coast states – Increasingly recognized in many other states ▪ Most common in young, large-breed, male dogs – History of exposure to warm, freshwater habitats – Typically immunocompetent and otherwise healthy animals ▪ Has also been reported in numerous other species – Including cats, horses, sheep, humans, a California bird, and zoo-captive animals including camels, big cats, and bears Pythiosis (Pythium insidiosumIVRA) ▪ Clinical Findings – Cutaneous or GI lesions ▪ Rarely both in same patient ▪ Systemic dissemination is rare ▪ In dogs, GI more frequent – Cutaneous pythiosis ▪ Nonhealing wounds or invasive masses ▪ Lymphadenomegaly often extension of infection (rather than reactive lymphadenopathy) Pythiosis (Pythium insidiosumIVRA) ▪ Clinical Findings – GI pythiosis ▪ Severe segmental transmural thickening of stomach, small intestine, colon or rectum – Inflammation often centered on submucosa ▪ Mucosal ulceration
    [Show full text]